ARCH Study: Is Romosozumab better than Alendronate for the Fracture-Prone?

It’s been 20 years since alendronate was approved to treat osteoporosis.  Although effective, bisphosphonates aren’t ideal. Romosozumab is an investigational monoclonal antibody that increases bone formation and decreases bone resorption. Is romosozumab a potentially better alternative to bisphosphonate therapy?  That’s what the ARCH study attempted to answer.

Guest Authors:  Yanqun Evonne Lee, MClinPharm and Joyce Yu-Chia Lee, PharmD

Music by Good Talk